More to Veterinary Anthelmintic ProHeart® than Green Book Indicates 

Analysis of the GenericsWeb Pipeline Patent Intelligence for Wyeth’s top selling veterinary anthelmintic ProHeart® (Moxidectin) shows that generic manufacturers should be wary of relying upon the US FDA Green Book for their critical patent expiry information.

Avandia® Patents Afford Protection Against Generic Competition 

Generic pharmaceutical manufacturers should proceed with caution when developing generic versions of Avandia®, (Rosiglitazone maleate), according to experts at GenericsWeb.

Lupin loses patent suit about Ramipril in America

MUMBAI: Pharmaceutical company Lupin on Thursday said a district court in the US has ruled against the company in a patent infringement suit filed by Sanofi-Aventis and King Pharmaceuticals.

Full Story of Relpax Patent Protection Not Told by Orange Book?

Pfizer’s oral anti-migraine medicine Relpax, (Eletriptan hydrobromide) appears to have more patent protection than meets the eye.    A report by GenericsWeb has uncovered an array of patent protection in terms of molecular form, active ingredient synthesis, formulations and medical use on not only the commercial product but also on potential commercial alternatives for generic competitors.

How to Calculate Standard Patent Expiry Dates and Data Exclusivity in Key Territories

Use this handy guide to navigate the calculation of patent expiry dates in US, Canada, Germany, Spain, France, United Kingdom and Australia, and also data exclusivity in the US, Canada, Europe and Australia.

Evergreening through Patent Strategies

One form of evergreening occurs when the originator manufacturer “stockpiles” patent protection by obtaining separate 20-year patents on multiple attributes of a single product. But many other evergreening strategies exist ...

 Strategies for early generic launch - Atorvastatin

The major constraining patent for Atorvastaitn is EP-00247633. Patentee is Warner-Lambert company. Priority date is 30 May 1986.  SPC for EP-00247633 will expire in Nov. 2011 in number of EU countries. However, in Slovenia, Czech R., Bulgaria, Hungary, Poland and Slovakia there is no national patents with link to  EP-00247633 as primary patent.

Strategies for successful generic launch in European Union - Sildenafil case